Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Allergy and Infectious Diseases (NIAID) National Institute on Drug Abuse (NIDA) National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00270257 |
Drug abuse and HIV/AIDS are serious global health problems. Injection drug use is currently the major mode of transmission of HIV in many countries. The purpose of this study is to determine the effectiveness of drug and risk reduction counseling combined with either substitution drug treatment with buprenorphine/naloxone (BUP/NX) or short-term detoxification with BUP/NX in preventing HIV transmission among injection drug users. Participants will be recruited for this study in China and Thailand.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Opioid-Related Disorders |
Drug: Buprenorphine/Naloxone |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase III Randomized Controlled Trial to Evaluate the Efficacy of Drug Treatment in Prevention of HIV Infection Among Opiate Dependent Injectors |
Estimated Enrollment: | 1460 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | May 2012 |
Estimated Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
|
Drug: Buprenorphine/Naloxone
Oral tablet
|
2: Experimental
Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
|
Drug: Buprenorphine/Naloxone
Oral tablet
|
Effective HIV prevention among injection drug users (IDUs) requires educating the at-risk population about HIV transmission and risky behavior, and providing the means for behavior change. Current treatment for opiate dependence focuses on reducing the frequency of drug use. BUP/NX is a combination pill currently used to treat opiate-dependent individuals. This trial will evaluate the effectiveness of two therapies in preventing HIV transmission among IDUs. Drug and risk reduction counseling combined with either substitution drug treatment with BUP/NX combined or short-term detoxification with BUP/NX will be compared in preventing the transmission of HIV among opiate-dependent individuals.
This study will last 4.5 years. Participants in this study will be randomly assigned to one of two treatment arms. Group 1 will receive BUP/NX substitution treatment. Group 2 will receive BUP/NX detoxification treatment. An initial 4-week safety and feasibility phase will involve the first 50 participants at each site and will last approximately 30 weeks. Study visits will occur every week and will include a physical exam and blood and urine collection.
The main treatment phase of the study will last 52 weeks. Participants in Group 1 will receive BUP/NX under the tongue, at first daily and then three times a week for 52 weeks. Participants assigned to Group 1 will take part in a BUP/NX reduction phase, which will occur between Weeks 47 and 52. Participants in Group 2 will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator. Participants assigned to Group 2 will receive BUP/NX for a maximum of 18 days; detoxification may be repeated at Week 26 if the participant is still injecting opiates.
In addition, participants in both groups will attend drug and risk reduction counseling will occur weekly. After the first 12 weeks, participants will return every 4 weeks for 10 more counseling sessions. HIV testing, risk assessment, and urine tests for opiates will occur at screening and at Weeks 26, 52, 78, 104, 130 and 156.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
China, Guangxi | |
Heng County Health and Epidemic Prevention Station | Recruiting |
Hengzhou Town, Guangxi, China, 532002I | |
Contact: Zhu Qiuying 86 771 530 5477 zhuqiuying@hotmail.com | |
Principal Investigator: Wei Liu, MD | |
China, Nanning | |
Guangxi Centers for Disease Control, China | Recruiting |
Guangxi, Nanning, China, 532002I | |
Contact: Michelle Rodolph +86 771 530 5477 mrodolp1@jhmi.edu | |
Principal Investigator: Brooks Jackson | |
Thailand | |
Research Institute for Health Sciences (RIHES) | Recruiting |
Chaing Mai, Thailand | |
Contact: Peter Lange 66-53-221-966 | |
Chiang Mai University - Department of Family Medicine | Recruiting |
Chiang Mai, Thailand | |
Contact: Auchara Sontirat (66 ) 53 -942 503 rhocsntr@chiangmai.ac.th | |
Chiang Mai University - Department of Psychiatry | Recruiting |
Chiang Mai, Thailand | |
Contact: Auchara Sontira (66 ) 53 -942 503 rhocsntr@chiangmai.ac.th | |
PEN House, Suthep Sub-District | Recruiting |
Chiang Mai, Thailand | |
Contact: Tasanai Vongchak (665) 394-2503 tvongcha@chiangmai.ac.th |
Study Chair: | David Metzger, PhD | Center for Studies of Addiction, University of Pennsylvania |
Study Chair: | Brooks Jackson, MD | Department of Pathology, Johns Hopkins University |
Study Chair: | David D. Celentano, DSc | Department of Epidemiology, Johns Hopkins School of Hygiene and Public Health |
Responsible Party: | DAIDS ( Rona Siskind ) |
Study ID Numbers: | HPTN 058 |
Study First Received: | December 22, 2005 |
Last Updated: | September 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00270257 |
Health Authority: | United States: Food and Drug Administration |
HIV Seronegativity Opiate Addiction Opiate Dependence |
Behavior, Addictive Sexually Transmitted Diseases, Viral Acquired Immunodeficiency Syndrome Disorders of Environmental Origin Opioid-Related Disorders Immunologic Deficiency Syndromes Naloxone |
Virus Diseases Buprenorphine HIV Infections Mental Disorders Sexually Transmitted Diseases Substance-Related Disorders Retroviridae Infections |
Communicable Diseases RNA Virus Infections Slow Virus Diseases Immune System Diseases Narcotic Antagonists Physiological Effects of Drugs Central Nervous System Depressants Narcotics Infection |
Pharmacologic Actions Sensory System Agents Therapeutic Uses Lentivirus Infections Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid |